Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
A veteran in cell therapy and oncology commercialisation
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Subscribe To Our Newsletter & Stay Updated
